Maze Therapeutics, Inc. (MAZE) Financial Statements
Free cash flow over the same period: -$106.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MAZEMaze Therapeutics, Inc.Follow MAZE — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 167.5 | — | — | |
| Research & development | 83.5 | 108.4 | 121.8 | |
| Operating income | 57.6 | -142.9 | -145.6 | |
| Pre-tax income | 53.4 | -131.1 | — | |
| Income tax | 1.2 | 0.0 | — | |
| Net income | 52.2 | -131.1 | -133.6 | |
| Diluted EPS ($) | 1.25 | -3.05 | -2.27 | |
| Diluted shares (mn) | 2.7 | 43.0 | — |
USD millions · SEC XBRL
Maze Therapeutics, Inc. — questions
- What is Maze Therapeutics, Inc.'s net income?
- -$133.6M over the twelve months to 2026-06-30.
- What is Maze Therapeutics, Inc.'s free cash flow?
- -$106.8M over the twelve months to 2026-06-30.
- What are Maze Therapeutics, Inc.'s diluted earnings per share?
- $-2.27 over the twelve months to 2026-06-30.
Every figure on this page comes from Maze Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.